Status:
UNKNOWN
Outcomes of Straight-line Flow Versus Angiosome-targeted Angioplasty in Treatment of Critical Lower Limb Ischemia
Lead Sponsor:
Kafrelsheikh University
Conditions:
Angioplasty
Critical Lower Limb Ischemia
Eligibility:
All Genders
Phase:
NA
Brief Summary
Peripheral arterial disease (PAD) affects more than 200 million people worldwide. Although over 50% are asymptomatic, it accounts for 4% of all amputations. The ischemic limb must be revascularized t...
Detailed Description
Introduction Peripheral arterial disease (PAD) affects more than 200 million people worldwide. Although over 50% are asymptomatic, it accounts for 4% of all amputations. The ischemic limb must be re...
Eligibility Criteria
Inclusion
- Patient with documented symptomatic infragenicular chronic arterial disease with or without supra-genicular lesion
- Diabetic or not
- Rutherford grades 4, 5 and 6
- The patient is able and willing to comply with study follow-up requirements.
Exclusion
- Contraindication for angioplasty
- unsuitable for angioplasty revascularization strategy
- claudication case
- tissue loss is considered to be primarily of venous etiology.
- Patient with full-thickness gangrene of the foot.
- Widespread infection of the lower limb needing amputation
Key Trial Info
Start Date :
January 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06127134
Start Date
January 1 2023
End Date
January 1 2024
Last Update
November 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kafrelsheikh University
Kafr ash Shaykh, Egypt